<DOC>
	<DOCNO>NCT00423098</DOCNO>
	<brief_summary>The study investigate efficacy safety enteric-coated mycophenolate sodium combination two different corticosteroid ( CS ) regimes induction remission lupus nephritis flare . Patients randomly allocate standard CS regimen ( group I ) reduce dose CS regimen ( group II )</brief_summary>
	<brief_title>Efficacy Safety Enteric-coated Mycophenolate Sodium Combination With Two Corticosteroid Regimens Treatment Lupus Nephritis Flare</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Inclusion criterion Male female patient systemic lupus erythematosus ( SLE ) ( least 4 classification criterion ) Aged ≥18 year , Proliferative lupus nephritis classify ISN/RPS class III IV Renal biopsy within last 24month precede study entry Proteinuria define &gt; 0.5 gram urine protein per gram urine creatinine screen baseline Clinical activity define one follow change renal function : Serum creatinine &gt; 1.0 mg/dl ( 88.4 μmol/l ) Microscopic hematuria define &gt; 5 red cell per high power field Presence cellular cast Exclusion criterion Patients calculate creatinine clearance &lt; 30 ml/min ( use CockcroftGault formula ) Patients receive intravenous ( i.v . ) corticosteroid bolus last 3 month , Patients receive oral i.v . cyclophosphamide last 3 month Patients receive mycophenolate mofetil ( MMF ) within precede 3 month Use antibody therapy within past 6 month Pregnant nursing ( lactate ) woman woman childbearing potential planning become pregnant , willing use effective mean contraception throughout study one month end study . Use investigational drug within 1 month enrollment ( except antibody : within 6 month enrollment History hypersensitivity study drug drug similar chemical structure , History malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Lupus Nephritis</keyword>
	<keyword>enteric-coated mycophenolate sodium</keyword>
	<keyword>EC-MPS</keyword>
	<keyword>Myfortic</keyword>
</DOC>